Golden
Infinity Pharmaceuticals

Infinity Pharmaceuticals

Biotechnology company focused on discovery and development of treatments for cancer and other related conditions

Infinity Pharmaceuticals is a Cambridge based Biotechnology Company working towards the discovery and development of treatments for cancer. The company’s lead product candidate, IPI-549 is an oral drug which selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). PI3K-gamma is a signal-transducing enzyme which is a critical modulator in cancer and immunity. As of March 2019, the drug is being studied for activity, safety, tolerability, pharmacokinetics, and pharmacodynamics.

Product

IPI-549 is being developed to inhibit the growth of cancer tumors. Research by the company has demonstrated transcriptional reprogramming of tumor-related macrophages by blocking PI3K-gamma signaling. It showed promise in promoting anti-tumor immune response by reprogramming pro-tumor phenotype to anti-tumor phenotype in the tumor microenvironment.

The drug is tested for use as monotherapy and in combination therapy with a PD-1 immune checkpoint inhibitor called nivolumab. The test study includes four parts; monotherapy and combination dose-escalation components with monotherapy expansion and combination expansion components. Approximately 200 patients with advanced cancer tumors relating to non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and triple negative breast cancer (TNBC) were selected as a part of this study. In combination expansion component study, the drug was evaluated with cancer patients suffering from NSCLC, HNSCC, and melanoma whose tumors show resistance to immune checkpoint blockade therapy.

History

Eric Lander, Frank Moss, and Michael Foely founded the company in 2001, and the company is headquartered in Cambridge, Massachusetts, United States.



Timeline

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Adriano Varassin

Employee



Andrea Lai

Employee



Andy Palmer

Employee



Andy Palmer

Employee



Chelsey Jensen

Employee



Daniela Lopez

Employee



David Drucker

Employee



David Michael Marks

Employee



David Nick

Employee



dennis underwood

Employee



Dennis Underwood

Employee



Igor Deyneko

Employee



Jamie Manning

Employee



Jarrett Goetz

Employee



Kevin Gilpin

Employee



MEGAN MOORE

Employee



Shawnise Beatty

Employee



Stephen Jamieson

Employee



Tiffany Ann Chen

Employee



Vaden Broaddus

Employee



Further reading

Title
Author
Link
Type
Date

IPI-549 - Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals

Web



PI3K-Gamma - Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals

Web



Documentaries, videos and podcasts

Title
Date
Link

Infinity Pharmaceuticals CEO on New Cancer Drug (6/03/13)

Jun 4, 2013

Companies

Company
CEO
Location
Products/Services









References